Catherine S Yang, MD in Boston, MA - Medicare Dermatology

Catherine S Yang, MD is a medicare enrolled "Dermatology" physician in Boston, Massachusetts. She went to Yale University School Of Medicine and graduated in 2012 and has 12 years of diverse experience with area of expertise as Dermatology. She is a member of the group practice Brigham And Women's Physicians Organization Inc and her current practice location is 221 Longwood Ave, Department Of Dermatology, Boston, Massachusetts. You can reach out to her office (for appointments etc.) via phone at (617) 732-4918.

Catherine S Yang is licensed to practice in Massachusetts (license number 265831) and she also participates in the medicare program. She accepts medicare assignments (which means she accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and her NPI Number is 1265794796.

Contact Information

	Catherine S Yang, MD
	221 Longwood Ave, Department Of Dermatology, Boston, MA 02115-5804
	(617) 732-4918
	(617) 582-6060

Physician's Profile

Full Name	Catherine S Yang
Gender	Female
Speciality	Dermatology
Experience	12 Years
Location	221 Longwood Ave, Boston, Massachusetts
Accepts Medicare Assignments	Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Catherine S Yang attended and graduated from Yale University School Of Medicine in 2012

NPI Data:

NPI Number: 1265794796
Provider Enumeration Date: 06/11/2012
Last Update Date: 10/31/2016

Medicare PECOS Information:

PECOS PAC ID: 7315190956
Enrollment ID: I20160706002069

Medical Identifiers

Medical identifiers for Catherine S Yang such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1265794796	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207N00000X	Dermatology	265831 (Massachusetts)	Primary

Medical Facilities Affiliation

Facility Name	Location	Facility Type
Brigham And Women's Hospital	Boston, MA	Hospital

Group Practice Association

Group Practice Name	Group PECOS PAC ID	No. of Members
Brigham And Women's Physicians Organization Inc	3870405988	2510

News Archive

Reflecting on FDA approval of new TB drug

Noting "the U.S. Food and Drug Administration (FDA) recently announced that it has approved a new treatment for multidrug-resistant tuberculosis (TB) that can be used as an alternative when other drugs fail," Kim Lufkin, communications officer at the Global Health Technologies Coalition (GHTC), writes in the coalition's "Breakthroughs" blog, "There is a pressing and urgent need for even more new TB drugs, which makes this new FDA approval so significant."

Best use of drug-eluting stents: When should they be avoided?

Compared with bare metal stents, drug-eluting stents substantially reduce the risk of angiographic and clinical recurrence but do not affect mortality or the short term or long term risk of myocardial infarction.

USW calls for greater attention to process safety within refining sector

The United Steelworkers said today that Wednesday's fire at ExxonMobil's Baton Rouge, La., refinery that injured one employee and two contractors demonstrates the urgency of the union's call for greater attention to process safety within the refining sector. This incident follows less than two weeks after the deadly Tesoro refinery explosion in Anacortes, Wash.

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

Spectrum Pharmaceuticals today announced that one of the two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target, having enrolled approximately 800 patients with non-invasive bladder cancer. The second Phase 3 clinical trial of apaziquone is expected to complete enrollment by the end of the year.

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

NOXXON Pharma today announced the successful completion of patient recruitment of its NOX-E36 Phase IIa clinical trial for the treatment of diabetic nephropathy. NOX-E36 is a Spiegelmer® that binds and neutralizes CCL2/MCP-1 (C-C Chemokine Ligand / Monocyte Chemoattractant Protein-1), a pro-inflammatory chemokine that plays an important role in the progression of diabetic nephropathy, the most common single cause of chronic kidney failure and end-stage renal disease.

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Catherine S Yang allows following entities to bill medicare on her behalf.

Entity Name	Brigham And Women's Physicians Organization Inc
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1033535497 PECOS PAC ID: 3870405988 Enrollment ID: O20150107001260

News Archive

Reflecting on FDA approval of new TB drug

Best use of drug-eluting stents: When should they be avoided?

USW calls for greater attention to process safety within refining sector

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Catherine S Yang is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Catherine S Yang, MD 221 Longwood Ave, Department Of Dermatology, Boston, MA 02115-5804 Ph: (617) 732-4918	Catherine S Yang, MD 221 Longwood Ave, Department Of Dermatology, Boston, MA 02115-5804 Ph: (617) 732-4918

News Archive

Reflecting on FDA approval of new TB drug

Best use of drug-eluting stents: When should they be avoided?

USW calls for greater attention to process safety within refining sector

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

Dermatology Doctors in Boston, MA

Erica Dommasch, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 330 Brookline Ave, Shapiro 2, Boston, MA 02215 Phone: 617-667-3753
Dr. Chantal Louise Cotter, MB BCH BAO Dermatology Medicare: Not Enrolled in Medicare Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6117
Dr. John J Croke, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 725 Albany St, Shapiro 8, Boston, MA 02118 Phone: 617-638-7420 Fax: 617-638-7289
Dr. Debjani Sahni, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 725 Albany Street, Shapiro 8, Boston, MA 02118 Phone: 617-638-7420 Fax: 617-638-7289
Dr. Joseph C Kvedar, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 50 Staniford St, Suite 200, Boston, MA 02114 Phone: 617-726-2914 Fax: 617-724-2135
Ryan Char Kelm, Dermatology Medicare: Medicare Enrolled Practice Location: 50 Staniford St # 250, Boston, MA 02114 Phone: 617-724-6960
Dr. David Attar Hashemi, MD, MBA Dermatology Medicare: Medicare Enrolled Practice Location: 50 Staniford St, Boston, MA 02114 Phone: 617-726-2914

Catherine S Yang, MD - Medicare Dermatology in Boston, MA

Contact Information

Physician's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Medical Facilities Affiliation

Group Practice Association

Reflecting on FDA approval of new TB drug

Best use of drug-eluting stents: When should they be avoided?

USW calls for greater attention to process safety within refining sector

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

Medicare Reassignments

Reflecting on FDA approval of new TB drug

Best use of drug-eluting stents: When should they be avoided?

USW calls for greater attention to process safety within refining sector

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

Reflecting on FDA approval of new TB drug

Best use of drug-eluting stents: When should they be avoided?

USW calls for greater attention to process safety within refining sector

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

Dermatology Doctors in Boston, MA